IMNN Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Imunon, Inc.'s net margin of -255.85%. Imunon, Inc.'s return on equity of -365% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Imunon, Inc. has a consensus price target of $64.47, signalling upside risk potential of 1553.01%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Imunon, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Imunon, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Imunon, Inc. has a beta of 1.937, which suggesting that the stock is 93.659% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Imunon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Imunon, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Imunon, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Imunon, Inc.'s net income of -$3.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Imunon, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon, Inc. is 16.43x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed, Inc. has a net margin of -- compared to Imunon, Inc.'s net margin of -120220%. Imunon, Inc.'s return on equity of -365% beat PAVmed, Inc.'s return on equity of 8.75%.

Imunon, Inc. has a consensus price target of $64.47, signalling upside risk potential of 1553.01%. On the other hand PAVmed, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 3243.47%. Given that PAVmed, Inc. has higher upside potential than Imunon, Inc., analysts believe PAVmed, Inc. is more attractive than Imunon, Inc..

Imunon, Inc. has a beta of 1.937, which suggesting that the stock is 93.659% more volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.095, suggesting its more volatile than the S&P 500 by 9.503%.

Imunon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.

Imunon, Inc. quarterly revenues are --, which are smaller than PAVmed, Inc. quarterly revenues of $5K. Imunon, Inc.'s net income of -$3.4M is higher than PAVmed, Inc.'s net income of -$6M. Notably, Imunon, Inc.'s price-to-earnings ratio is -- while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon, Inc. is 16.43x versus 293.08x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PDS Biotechnology Corp. has a net margin of -- compared to Imunon, Inc.'s net margin of --. Imunon, Inc.'s return on equity of -365% beat PDS Biotechnology Corp.'s return on equity of -196.47%.

Imunon, Inc. has a consensus price target of $64.47, signalling upside risk potential of 1553.01%. On the other hand PDS Biotechnology Corp. has an analysts' consensus of $7.50 which suggests that it could grow by 762.07%. Given that Imunon, Inc. has higher upside potential than PDS Biotechnology Corp., analysts believe Imunon, Inc. is more attractive than PDS Biotechnology Corp..

Imunon, Inc. has a beta of 1.937, which suggesting that the stock is 93.659% more volatile than S&P 500. In comparison PDS Biotechnology Corp. has a beta of 1.107, suggesting its more volatile than the S&P 500 by 10.743%.

Imunon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon, Inc. pays -- of its earnings as a dividend. PDS Biotechnology Corp. pays out -- of its earnings as a dividend.

Imunon, Inc. quarterly revenues are --, which are smaller than PDS Biotechnology Corp. quarterly revenues of --. Imunon, Inc.'s net income of -$3.4M is higher than PDS Biotechnology Corp.'s net income of -$9M. Notably, Imunon, Inc.'s price-to-earnings ratio is -- while PDS Biotechnology Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon, Inc. is 16.43x versus -- for PDS Biotechnology Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Imunon, Inc.'s net margin of --. Imunon, Inc.'s return on equity of -365% beat Palatin Technologies's return on equity of --.

Imunon, Inc. has a consensus price target of $64.47, signalling upside risk potential of 1553.01%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Imunon, Inc., analysts believe Palatin Technologies is more attractive than Imunon, Inc..

Imunon, Inc. has a beta of 1.937, which suggesting that the stock is 93.659% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Imunon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Imunon, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Imunon, Inc.'s net income of -$3.4M is higher than Palatin Technologies's net income of --. Notably, Imunon, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon, Inc. is 16.43x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.